000300739 001__ 300739
000300739 005__ 20251218151529.0
000300739 0247_ $$2pmid$$apmid:40307530
000300739 0247_ $$2ISSN$$a0938-7994
000300739 0247_ $$2ISSN$$a1432-1084
000300739 0247_ $$2ISSN$$a1613-3749
000300739 0247_ $$2ISSN$$a1613-3757
000300739 0247_ $$2ISSN$$a(ISSN
000300739 0247_ $$2ISSN$$aDES
000300739 0247_ $$2ISSN$$aSUPPLEMENTS)
000300739 0247_ $$2doi$$a10.1007/s00330-025-11603-3
000300739 0247_ $$2altmetric$$aaltmetric:177040985
000300739 037__ $$aDKFZ-2025-00899
000300739 041__ $$aEnglish
000300739 082__ $$a610
000300739 1001_ $$aCarletti, Filippo$$b0
000300739 245__ $$aDiagnostic accuracy of multiparametric MRI for detecting unconventional prostate cancer histology: a systematic review and meta-analysis.
000300739 260__ $$aHeidelberg$$bSpringer$$c2026
000300739 3367_ $$2DRIVER$$aarticle
000300739 3367_ $$2DataCite$$aOutput Types/Journal article
000300739 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766067265_2624437$$xReview Article
000300739 3367_ $$2BibTeX$$aARTICLE
000300739 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300739 3367_ $$00$$2EndNote$$aJournal Article
000300739 500__ $$a2026 Jan;36(1):17-29 / Epub 2025 Apr 30
000300739 520__ $$aAccurate detection of unconventional histologies (UH) in prostate cancer (PCa) is crucial for treatment planning and prognosis. This systematic review and meta-analysis aimed to evaluate the accuracy of multiparametric magnetic resonance imaging (mpMRI) in detecting UH on prostatectomy, particularly cribriform architecture (CA) and intraductal carcinoma (IDC-P), in patients with localized PCa.A literature search was conducted in major databases for studies published after 2000. Seventeen articles fulfilled the inclusion criteria and were eligible for qualitative analysis. Five studies met the inclusion criteria for meta-analysis.The pooled sensitivity and specificity of mpMRI (Prostate Imaging Reporting and Data System (PI-RADS) cutoff 3) to detect cribriform architecture were 0.91 and 0.29. The proportion of cribriform lesions increased with higher PI-RADS scores (23.2% for PI-RADS 1-2 to 66.7% for PI-RADS 5). For intraductal carcinoma (IDC-P), two studies found that IDC-P lesions were visible on mpMRI and had lower apparent diffusion coefficient (ADC) values compared to acinar prostate cancer. Four studies evaluating combined CA/IDC-P found sensitivities ranging from 33 to 100%. Lower ADC values were associated with CA/IDC-P in some studies, but not in others. Overall, mpMRI demonstrated promising sensitivity but moderate specificity in detecting these aggressive histological variants, with continued challenges in accurate sampling and characterization of mpMRI.mpMRI shows high sensitivity but moderate specificity in detecting cribriform architecture in PCa, especially for high PI-RADS scores. These findings support the use of mpMRI for UH detection, but caution is advised in clinical interpretation. Larger prospective studies are needed to validate these results before routine clinical application. We studied how effective MRI is at identifying different UH of PCa, such as cribriform architecture and intraductal carcinoma. MRI is accurate at detecting these cancers when they are present, but it also produces a significant number of false positives. More research is needed to standardize imaging protocols and histological definition and ensure an accurate diagnosis.Question The accurate detection of unconventional histologies in prostate cancer, particularly cribriform architecture and intraductal carcinoma, is challenging but crucial for treatment planning and prognosis. Findings mpMRI shows high sensitivity (91%) but low specificity (29%) for detecting cribriform architecture, with detection rates increasing proportionally with higher PI-RADS scores. Clinical relevance mpMRI can effectively detect aggressive unconventional histologies in prostate cancer, though its moderate specificity suggests the need for careful interpretation. This aids in risk stratification and treatment planning, potentially improving patient outcomes.
000300739 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000300739 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000300739 7001_ $$aMaggi, Martina$$b1
000300739 7001_ $$aFazekas, Tamas$$b2
000300739 7001_ $$aRajwa, Pawel$$b3
000300739 7001_ $$aNicoletti, Rossella$$b4
000300739 7001_ $$aOlivier, Jonathan$$b5
000300739 7001_ $$aPreisser, Felix$$b6
000300739 7001_ $$aSoeterik, Timo F W$$b7
000300739 7001_ $$aGiganti, Francesco$$b8
000300739 7001_ $$aMartini, Alberto$$b9
000300739 7001_ $$aHeidegger, Isabel$$b10
000300739 7001_ $$aKasivisvanathan, Veeru$$b11
000300739 7001_ $$aPradère, Benjamin$$b12
000300739 7001_ $$aPloussard, Guillaume$$b13
000300739 7001_ $$0P:(DE-HGF)0$$aHadaschik, Boris$$b14
000300739 7001_ $$aMoro, Fabrizio Dal$$b15
000300739 7001_ $$avan den Bergh, Roderick C N$$b16
000300739 7001_ $$aMarra, Giancarlo$$b17
000300739 7001_ $$aGandaglia, Giorgio$$b18
000300739 7001_ $$00000-0002-4178-373X$$aZattoni, Fabio$$b19
000300739 7001_ $$0P:(DE-HGF)0$$aKesch, Claudia$$b20
000300739 7001_ $$aParty, EAU-YAU Prostate Cancer Working$$b21$$eCollaboration Author
000300739 773__ $$0PERI:(DE-600)1472718-3$$a10.1007/s00330-025-11603-3$$n1$$p17-29$$tEuropean radiology$$v36$$x0938-7994$$y2026
000300739 909CO $$ooai:inrepo02.dkfz.de:300739$$pVDB
000300739 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000300739 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000300739 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000300739 9141_ $$y2025
000300739 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-28$$wger
000300739 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-28$$wger
000300739 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR RADIOL : 2022$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-28
000300739 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR RADIOL : 2022$$d2024-12-28
000300739 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x0
000300739 980__ $$ajournal
000300739 980__ $$aVDB
000300739 980__ $$aI:(DE-He78)ED01-20160331
000300739 980__ $$aUNRESTRICTED